Expression and Amplification of Topoisomerase-2α in Type 1 and Type 2 Papillary Renal Cell Carcinomas and Its Correlation with HER2/neu Amplification

2011 ◽  
Vol 17 (3) ◽  
pp. 697-703 ◽  
Author(s):  
Fusun Duzcan ◽  
Suleyman Ender Duzcan ◽  
Sait Sen ◽  
Kutsal Yorukoglu ◽  
Vildan Caner ◽  
...  
Keyword(s):  
Renal Cell ◽  
Renal Cell Carcinomas

scholarly journals Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Jian He ◽  
Kefeng Zhou ◽  
Bin Zhu ◽  
Gutian Zhang ◽  
Xiaogong Li ◽  
...  
Keyword(s):  
Renal Cell ◽  
Gene Fusions ◽  
Renal Cell Carcinomas ◽  
Contrast Enhanced Ct ◽  
Contrast Enhanced ◽  
Enhanced Ct ◽  
Xp11.2 Translocation ◽  
Clinical Records

Purpose. To compare the differences of CT characteristics between renal cell carcinomas (RCCs) associated with Xp11.2 translocation/TFE3 gene fusions (Xp11.2 RCCs) and papillary cell renal cell carcinomas (PRCCs). Methods. CT images and clinical records of 64 patients (25 Xp11.2 RCCs, 15 type 1 and 24 type 2 PRCCs) were analyzed and compared retrospectively. Results. Xp11.2 RCC more frequently affected young (30.7±8.7 years) women (16/25, 64%) with gross hematuria (12/25, 48%), while PRCC more frequently involved middle-aged (54.8±11.1 years) men (28/39, 71.8%) asymptomatically. Xp11.2 RCC tended to be heterogeneous density with some showing circular calcification. Lesion sizes of Xp11.2 RCC (5.4±2.2 cm) and type 2 PRCC (5.7±2.5 cm) were significantly larger than that of type 1 PRCC (3.8±1.8 cm). Xp11.2 RCC contained more cystic components (22/25, 88%) than type 1 PRCC (all solid) and type 2 PRCC (9/24, 36.0%). Type 1 PRCC (13/15, 86.7%) and Xp11.2 RCC (21/25, 84.0%) showed more clear boundary than type 2 PRCC (12/24, 50.0%). Conclusion. CT features including diameter, boundary, attenuation, nature, and circular calcification of the tumor, combined with demographic information and symptoms, may be useful to differentiate Xp11.2 RCC from different subtypes of PRCC.

Cytogenetic and morphologic typing of papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors

2004 ◽  
Vol 200 (4) ◽  
pp. 303
Author(s):  
B. Gunawan ◽  
A. Von Heydebreck ◽  
T. Fritsch ◽  
W. Huber ◽  
R.-H. Ringert ◽  
...  
Keyword(s):  
Renal Cell ◽  
Renal Cell Carcinomas ◽  
Cytogenetic Evolution

scholarly journals Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2

2019 ◽  
Vol 37 (10) ◽  
pp. 721-726 ◽  
Author(s):  
Emily C.L. Wong ◽  
Richard Di Lena ◽  
Rodney H. Breau ◽  
Frederic Pouliot ◽  
Antonio Finelli ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Prognostic Predictor

scholarly journals Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma

2009 ◽  
Vol 15 (4) ◽  
pp. 1162-1169 ◽  
Author(s):  
Tobias Klatte ◽  
Allan J. Pantuck ◽  
Jonathan W. Said ◽  
David B. Seligson ◽  
Nagesh P. Rao ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Tumor Profiling

Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery

2015 ◽  
Vol 34 (5) ◽  
pp. 687-693 ◽  
Author(s):  
Rodrigo A. Ledezma ◽  
Edris Negron ◽  
Gladell P. Paner ◽  
Chris Rjepaj ◽  
Danny Lascano ◽  
...  
Keyword(s):  
Renal Cell ◽  
Survival Outcomes ◽  
Renal Cell Carcinomas ◽  
Similar Survival

Gene expression profiling identifies two distinct papillary renal cell carcinoma (RCC) subgroups of contrasting prognosis

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4503-4503
Author(s):  
B. T. Teh ◽  
X. J. Yang ◽  
M. Tan ◽  
H. L. Kim ◽  
W. Stadler ◽  
...  
Keyword(s):  
Gene Expression ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Comparative Genomic ◽  
Low Grade ◽  
Class 1

4503 Background: Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a disproportionately limited understanding of its underlying genetic programs. There is no effective therapy for metastatic PRCC, and patients are often excluded from kidney cancer trials. A morphological classification of PRCC into Type 1 and Type 2 tumors has been recently proposed, but its biological relevance remains uncertain. Methods: We studied the gene expression profiles of 34 cases of PRCC using Affymetrix HGU133 Plus 2.0 arrays (54,675 probe sets) using both unsupervised and supervised analysis. Comparative genomic microarray analysis (CGMA) was used to infer cytogenetic aberrations, and pathways were ranked with a curated database. Expression of selected genes was validated by immunohistochemistry in 34 samples, with 15 independent tumors. Results: We identified two highly distinct molecular PRCC subclasses with morphologic correlation. The first class, with excellent survival, corresponded to three histological subtypes: Type 1, low-grade Type 2 and mixed Type 1/low-grade Type 2 tumors. The second class, with poor survival, corresponded to high-grade Type 2 tumors (n = 11). Dysregulation of G1/S and G2/M checkpoint genes were found in Class 1 and Class 2 tumors respectively, alongside characteristic chromosomal aberrations. We identified a 7-transcript predictor that classified samples on cross-validation with 97% accuracy. Immunohistochemistry confirmed high expression of cytokeratin 7 in Class 1 tumors, and of topoisomerase IIα in Class 2 tumors. Conclusions: We report two molecular subclasses of PRCC, which are biologically and clinically distinct, which may be readily distinguished in a clinical setting. This may also have therapeutic implications. No significant financial relationships to disclose.

MP36-01 CAN MULTIPHASE CT SCAN DISTINGUISH BETWEEN TYPE 1 AND TYPE 2 PAPILLARY RENAL CELL CARCINOMA? A RETROSPECTIVE ANALYSIS

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Michelle McDonald ◽  
Hak Lee ◽  
Vipulkumar Dadhania ◽  
Song Wang ◽  
Ryan Kopp ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Ct Scan ◽  
Cell Carcinoma ◽  
Retrospective Analysis ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Multiphase Ct

scholarly journals Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell Responses

2004 ◽  
Vol 10 (18) ◽  
pp. 6360S-6366S ◽  
Author(s):  
Patricia Rayman ◽  
Amy K. Wesa ◽  
Amy L. Richmond ◽  
Tanya Das ◽  
Kaushik Biswas ◽  
...  
Keyword(s):  
T Cell ◽  
Renal Cell ◽  
T Cell Responses ◽  
Renal Cell Carcinomas ◽  
Cell Responses

scholarly journals Comparison of clinicopathologic parameters and oncologic outcomes between type 1 and type 2 papillary renal cell carcinoma

BMC Urology ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Xiang Le ◽  
Xiang-Bo Wang ◽  
Hao Zhao ◽  
Ren-Fu Chen ◽  
Peng Ge
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Size ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Oncologic Outcomes ◽  
Angiolymphatic Invasion ◽  
Clinicopathologic Parameters ◽  
Foamy Macrophages

Abstract Background To compare the clinicopathologic parameters and oncologic outcomes between type 1 and type 2 papillary renal cell carcinoma (PRCC). Methods This study was approved by the review board (NO.XYFY2019-KL032–01). Between 2007 and 2018, 52 consecutive patients who underwent surgery at a single tertiary referral hospital were included. Clinicopathologic and survival data were collected and entered into a database. The Kaplan-Meier method, and univariate and multivariate Cox proportional hazard regression analyses were performed to estimate progression-free survival (PFS) and cancer-specific survival (CSS). Results Of the 52 patients, 24 (46.2%) were diagnosed with type 1 PRCC, and 28 (53.8%) had type 2 PRCC. The mean tumor size was 4.8 ± 2.5 cm. The two subtypes displayed different morphological features: foamy macrophages were more common in type 1 PRCC, while eosinophils and microvascular angiolymphatic invasion were more frequent in type 2 PRCC. Type 2 cases showed higher tumor stage and World Health Organization/International Society of Urological Pathology (WHO/ISUP) grade than type 1 cases (T3-T4: 43% vs 17%, P = 0.041; G3-G4: 43% vs 8%, P = 0.005). In univariate analysis, type 2 PRCC had a lower probability for PFS and CSS than patients with type 1 PRCC (P = 0.016, P = 0.049, log-rank test, respectively). In multivariate analysis, only WHO/ISUP grade (HR 11.289, 95% CI 2.303–55.329, P = 0.003) and tumor size (HR 1.244, 95% CI 1.034–1.496, P = 0.021) were significantly associated with PFS. Conclusions PRCC subtype displayed different morphological features: foamy macrophages, eosinophils and microvascular angiolymphatic invasion are pathologic features that may aid in the distinction of the two subtypes. Histologic subtype of PRCC is not an independent prognostic factor and only WHO/ISUP grade and tumor size were independent predictors for PFS.

Sign in / Sign up

Export Citation Format

Share Document